Evidence map›Paper›PMID 31527024›Full record

ArticleAntimicrobial agents and chemotherapy2019

Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses.

Chunfeng Li, Shulong Zu, Yong-Qiang Deng, Dapei Li, Kislay Parvatiyar, Natalie Quanquin, Jingzhe Shang, Nina Sun, Jiaqi Su, Zhenyang Liu and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
20.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 111 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Antiviral effects of azithromycin: A narrative review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Repurposing of antibiotics for clinical management of COVID-19: a narrative review.Annals of clinical microbiology and antimicrobials · 2021
    Review
  19. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Chunfeng LiCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China gcheng@mednet.ucla.edu qincf@bmi.ac.cn chunfeng@stanford.edu.
Shulong ZuCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Yong-Qiang DengDepartment of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
Dapei LiCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
Kislay ParvatiyarDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Natalie QuanquinDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Jingzhe ShangCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
Nina SunCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Jiaqi SuUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Zhenyang LiuUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Min WangUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Saba R AliyariDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Xiao-Feng LiDepartment of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
Aiping WuCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
Feng MaCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
Yi ShiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Karin Nielsevn-SainesDivision of Pediatric Infectious Diseases, David Geffen School of Medicine, UCLA, Marion Davies Children's Health Center, Los Angeles, California, USA.
Jae U JungDepartment of Molecular Microbiology and Immunology and Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Zilkha Neurogenetic Institute, Los Angeles, California, USA.ORCID http://orcid.org/0000-0003-4559-8774
Frank Xiao-Feng QinCenter for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005; Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China.
Cheng-Feng QinDepartment of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China gcheng@mednet.ucla.edu qincf@bmi.ac.cn chunfeng@stanford.edu.
Genhong ChengDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA. gcheng@mednet.ucla.edu qincf@bmi.ac.cn chunfeng@stanford.edu.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CNUniversity of California, Los Angeles · USWuhan Institute of Virology · CNUniversity of Southern California · US

Funding

Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKVR01AI140718 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG, JUNG, JAE U · 2018 to 2022
$3.8M
Role of autophagy for Zika virus lifecycleR21AI129496 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2017 to 2018
$454k
NIAID NIH HHS R01 AI069120NIAID NIH HHS R01 AI140718NIAID NIH HHS R21 AI129496
6 · The paper itself

Abstract

Azithromycin (AZM) is a widely used antibiotic, with additional antiviral and anti-inflammatory properties that remain poorly understood. Although Zika virus (ZIKV) poses a significant threat to global health, there are currently no vaccines or effective therapeutics against it. Herein, we report that AZM effectively suppresses ZIKV infection

Identifiers

PMID31527024
PMCPMC6879226
OpenAlexW2972946514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.